А можно ли без неё?

Олег, То, что описано в этой статье не является новым. Явление химеризма после гемотрансфузий и трансплантации органов известно уже более 10 лет. Еще в 1999г мы переливали клетки костного мозга больным после трансплантации сердца в Филадельфийском госпитале Temple. Проблема в том, что не у всех это работает одинаково. Одна из ранних статей на эту тему Transfusion. 2001 Mar;41(3):419-26 Microchimerism, GVHD, and tolerance in solid organ transplantation. Triulzi DJ, Nalesnik MA. Department of Pathology, University of Pittsburgh Medical Center and the Institute for Transfusion Medicine, Pittsburgh, PA 15213, USA. dtriulzi@itxm.org Abstract The phenomenon of microchimerism and its relationship to long-term graft tolerance is an area of active study. The ability to establish a tolerant state has been enhanced with current immunosuppressive drugs and emerging therapies such as donor HPC infusions. An undesirable outcome of host-donor WBC interaction is GVHD. GVHD is a rare complication reported most frequently in liver transplantation. Two cases of GVHD reported in recipients of organs from donors homozygous for a shared HLA haplotype would support a policy of avoiding the use of these donors. TA-GVHD is very rare in solid organ transplant recipients, with only four published cases; only two had convincing supportive evidence and one of these had an underlying hematologic abnormality. These few cases do not support a policy of routine irradiation of cellular blood components for all solid organ transplant recipients. The use of donor HPC infusions to enhance chimerism and graft tolerance has increased the number of GVHD cases observed (usually mild) and decreased the severity and number of rejection episodes. The long-term effects of donor HPC infusions on graft survival is under investigation.

Всё, я уже разобралась сама.  Имеется ввиду генетически разнородный материал, а это похоже на химеру с туловищем козы и головой льва!.